Compare EHang Holdings Ltd - ADR (EH) vs TG Therapeutics Inc (TGTX) Price & Performance

EHang Holdings (EH) trades at $5.41, down 0.73% on the day, with technical indicators showing bearish momentum and mixed sentiment. The company reported Q1 2026 revenue of $418 million, flat year-over-year but sharply lower than the prior quarter due to delivery timing. Despite a strong gross margin of 61.53%, the company continues to post significant net losses (-$276 million in 2025) with negative ROE and ROA. Recent news highlights both operational progress in eVTOL certification and a $30 million share repurchase program announced in June 2026.

The outlook remains challenging with persistent losses and high cash burn, though analyst consensus suggests modest upside to the $6.97 price target. Key risks include execution on commercialization, competitive pressures in the air mobility sector, and reliance on financing activities to fund operations. The stock presents speculative appeal for investors betting on long-term eVTOL adoption, but requires careful risk management given the current financial profile.

TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.

The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.